Vivo Capital’s Unicycive Therapeutics UNCY Stock Holding History

Vivo Capital’s Portfolio UNCY Stock Details UNCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.58M	Sell	550,000 -1,239,916	-69%	-$9.15M	0.24%	42
2026 Q1	$11.8M	Hold	1,789,916	–	–	0.98%	28
2025 Q4	$10.3M	Hold	1,789,916	–	–	0.67%	33
2025 Q3	$7.8M	Buy	1,789,916 +652,901	+57%	+$2.85M	0.63%	36
2025 Q2	$5.42M	Hold	1,137,015	–	–	0.56%	35
2025 Q1	$6.54M	Buy	1,137,015 +140,000	+14%	+$854K	0.87%	27
2024 Q4	$7.92M	Buy	997,015 +550,000	+123%	+$3.04M	0.89%	27
2024 Q3	$1.82M	Buy	447,015 +100,000	+29%	+$402K	0.15%	37
2024 Q2	$1.74M	Hold	347,015	–	–	0.16%	35
2024 Q1	$4.79M	Hold	347,015	–	–	0.38%	36
2023 Q4	$3.01M	Hold	347,015	–	–	0.25%	41
2023 Q3	$2.98M	Buy	+347,015	New	+$3.25M	0.33%	41

Other funds holding UNCY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Vivo Capital's UNCY Position: Q2 2026 in Review

Vivo Capital reduced its Unicycive Therapeutics (UNCY) stake by 69% in Q2 2026, selling an estimated $9.15M and leaving 550,000 shares worth $2.58M. The position accounts for 0.24% of the portfolio, ranked #42.

Vivo Capital first reported a position in UNCY in Q3 2023 and has held it in 12 quarters since. The position peaked at $11.8M in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

Vivo Capital held 550,000 shares of Unicycive Therapeutics worth $2.58M as of Q2 2026.
Vivo Capital sold 1,239,916 Unicycive Therapeutics shares in Q2 2026, an estimated $9.15M.
Unicycive Therapeutics made up 0.24% of Vivo Capital's portfolio in Q2 2026, its #42 holding.
Vivo Capital first reported a position in Unicycive Therapeutics in Q3 2023 and has held it in 12 quarters since.
Vivo Capital's Unicycive Therapeutics position peaked at $11.8M in Q1 2026.
80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.